Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer

Clinical Lung Cancer

Volumn 14, Issue 4, 2013, Pages 322-332

  Gadgeel, Shirish M ^a,b   Wozniak, Antoinette ^a,b  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1 phosphatidylinositol 3 kinase antagonists and inhibitors; Carcinoma; Drug resistance; Epidermal growth factor antagonists and inhibitors; Neoplasm physiology; Non small cell lung cancer drug therapy; Protein kinase inhibitors; Receptor

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFATINIB; ANTINEOPLASTIC AGENT; BUPARLISIB; CARBOPLATIN; CISPLATIN; COMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MKC 1; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NERATINIB; PEMETREXED; PICTILISIB; RIDAFOROLIMUS; SELUMETINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; XL 147; XL 765;

APOPTOSIS; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; EXON; GENE DELETION; GENE DUPLICATION; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84878797896     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.12.001     Document Type: Review

References (92)

1. D. Veale, T. Ashcroft, C. Marsh Epidermal growth factor receptors in non-small cell lung cancer Br J Cancer 55 1987 513 516
2. N.E. Hynes, H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354
3. W. Pao, J. Chmielecki Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat Rev Cancer 10 2010 760 774
4. V.A. Miller, M.G. Kris, N. Shah Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 2004 1103 1109
5. M. Fukuoka, S. Yano, G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected] J Clin Oncol 21 2003 2237 2246
6. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
7. J.G. Paez, P.A. Jänne, J.C. Lee EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
8. J.Y. Wu, S.G. Wu, C.H. Yang Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response Clin Cancer Res 14 2008 4877 4882
9. M. He, M. Capelletti, K. Nafa EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma Clin Cancer Res 18 2012 1790 1797
10. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
11. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
12. E. Bria, M. Milella, F. Cuppone Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis Ann Oncol 22 2011 2277 2285
13. Y.J. Lee, B.C. Cho, S.H. Jee Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer J Clin Oncol 28 2010 487 492
14. R. Rosell, T. Moran, C. Queralt Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
15. T. Mitsudomi, Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer CancerSci 98 2007 1817 1824
16. L. Paz-Ares, D. Soulières, I. Melezínek Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis J Cell Mol Med 14 2010 51 69
17. P. Liu, H. Cheng, T.M. Roberts Targeting the phosphoinositide 3-kinase pathway in cancer Nat Rev Drug Discov 8 2009 627 644
18. T.L. Yuan, H.S. Choi, A. Matsui Class 1A PI3K regulates vessel integrity during development and tumorigenesis Proc Natl Acad Sci U S A 105 2008 9739 9744
19. K.D. Courtney, R.B. Corcoran, J.A. Engelman The PI3K pathway as drug target in human cancer J Clin Oncol 28 2010 1075 1083
20. B. Vanhaesebroeck, J. Guillermet-Guibert, M. Graupera The emerging mechanisms of isoform-specific PI3K signalling Nat Rev Mol Cell Biol 11 2010 329 341
21. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562
22. R.J. Dowling, I. Topisirovic, B.D. Fonseca Dissecting the role of mTOR: lessons from mTOR inhibitors Biochim Biophys Acta 1804 2010 433 439
23. P. Rusconi, E. Caiola, M. Broggini RAS/RAF/MEK inhibitors in oncology Curr Med Chem 19 2012 1164 1176
24. E. Castellano, J. Downward RAS interaction with PI3K: more than just another effector pathway Genes Cancer 2 2011 261 274
25. J.A. Engelman, P.A. Jänne Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res 14 2008 2895 2899
26. H. Yasuda, S. Kobayashi, D.B. Costa 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications Lancet Oncol 13 2012 e23 e31
27. C.H. Yun, K.E. Mengwasser, A.V. Toms The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci U S A 105 2008 2070 2075
28. D.W. Bell, I. Gore, R.A. Okimoto Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR Nat Genet 37 2005 1315 1316
29. L.V. Sequist, B.A. Waltman, D. Dias-Santagata Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 2011 75ra26
30. M. Inukai, S. Toyooka, S. Ito Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer Cancer Res 66 2006 7854 7858
31. E. Jabbour, H. Kantarjian, D. Jones Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy Blood 112 2008 53 55
32. K.S. Nguyen, S. Kobayashi, D.B. Costa Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway Clin Lung Cancer 10 2009 281 289
33. V. Hirsh Afatinib (BIBW 2992) development in non-small-cell lung cancer Future Oncol 7 2011 817 825
34. L.V. Sequist, B. Besse, T.J. Lynch Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer J Clin Oncol 28 2010 3076 3083
35. E.L. Kwak, R. Sordella, D.W. Bell Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci U S A 102 2005 7665 7670
36. D. Li, L. Ambrogio, T. Shimamura BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
37. T. Mok, D.R. Spigel, K. Park Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC) J Clin Oncol 28 2010 abstract 7537
38. Miller V, Hirsh V, Cadranel J, et al. Subgroup analysis of LUX-Lung. A randomized phase III trial of afatinib (BIBW 2992) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib. Paper presented at the Chicago Multidisciplinary Symposium In Thoracic Oncology, Chicago, December 9, 2010; abstract LBPL3.
39. N. Godin-Heymann, L. Ulkus, B.W. Brannigan The T790M " gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor Mol CancerTher 7 2008 874 879
40. W. Zhou, D. Ercan, L. Chen Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 2009 1070 1074
41. Clinicaltrials.gov. [Web site] Study to Evaluate Safety, pharmacokinetics, and preliminary efficacy of CO-1686 in previously treated mutant epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) http://www.clinicaltrials.gov/ct2/show/NCT01526928 Accessed: March 7, 2012
42. A.O. Walter, R. Tjin, H. Haringsma CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; November 12-16, 2011; San Francisco, CA Mol Cancer Ther 10 11 Suppl 2011 Abstract nr C189
43. J.A. Engelman, K. Zejnullahu, T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
44. J. Bean, C. Brennan, J.Y. Shih MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci U S A 104 2007 20932 20937
45. A.B. Turke, K. Zejnullahu, Y.L. Wu Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 17 2010 77 88
46. H.A. Wakelee, S.N. Gettinger, J.A. Engelman A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC) J Clin Oncol 2010 28 abstract 3017 www.asco.org Accessed: December 31, 2012
47. S. Yano, W. Wang, Q. Li Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 68 2008 9479 9487
48. H. Uramoto, H. Shimokawa, T. Hanagiri Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma Lung Cancer 73 2011 361 365
49. T. Yamada, K. Matsumoto, W. Wang Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer Clin Cancer Res 16 2010 174 183
50. H. Yamamoto, H. Shigematsu, M. Nomura PIK3CA mutations and copy number gains in human lung cancers Cancer Res 68 2008 6913 6921
51. G. Jin, M.J. Kim, H.S. Jeon PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers Lung Cancer 69 2010 279 283
52. C.J. Marsit, S. Zheng, K. Aldape PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration Hum Pathol 36 2005 768 776
53. J.A. Engelman, T. Mukohara, K. Zejnullahu Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer J Clin Invest 116 2006 2695 2706
54. Y. Kokubo, A. Gemma, R. Noro Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (Iressa) Br J Cancer 92 2005 1711 1719
55. A. Guo, J. Villén, J. Kornhauser Signaling networks assembled by oncogenic EGFR and c-Met Proc Natl Acad Sci U S A 105 2008 692 697
56. S. La Monica, M. Galetti, R.R. Alfieri Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines Biochem Pharmacol 78 2009 460 468
57. M.L. Sos, M. Koker, B.A. Weir PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR Cancer Res 69 2009 3256 3261
58. D. Li, T. Shimamura, H. Ji Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy Cancer Cell 12 2007 81 93
59. S.A. Wander, B.T. Hennessy, J.M. Slingerland Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy J Clin Invest 121 2011 1231 1241
60. J.C. Soria, F.A. Shepherd, J.Y. Douillard Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors Ann Oncol 20 2009 1674 1681
61. S.M. Brachmann, J. Kleylein-Sohn, S. Gaulis Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 mechanism of action across a broad range of concentrations Mol Cancer Ther 11 2012 1747 1757
62. A.C. Faber, K.K. Wong, J.A. Engelman Differences underlying EGFR and HER2 oncogene addiction Cell Cycle 9 2010 851 852
63. A.C. Faber, D. Li, Y. Song Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition Proc Natl Acad Sci U S A 106 2009 19503 19508
64. H.C. Gong, S. Wang, G. Mayer 2011 Signatures of drug sensitivity in nonsmall cell lung cancer Int J Proteomics 2011 2011 215496
65. I.S. Donev, W. Wang, T. Yamada Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer Clin Cancer Res 17 2011 2260 2269
66. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
67. K.A. Price, C.G. Azzoli, L.M. Krug Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer J Thorac Oncol 5 2010 1623 1629
68. D. Benjamin, M. Colombi, C. Moroni Rapamycin passes the torch: a new generation of mTOR inhibitors Nat Rev Drug Discov 10 2011 868 880
69. Clinicaltrials.gov. [Web site] Study Assessing Safety, pharmacokinetics and efficacy of CC-223 with either erlotinib or oral azacitidine in advanced non-small cell lung cancer http://www.clinicaltrials.gov/ct2/show/NCT01545947 Accessed: March 12, 2012
70. Maira M, Menezes D, Pecchi S, et al. NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; April 17-21, 2010; Washington, DC. Abstract 4497.
71. Voliva CF, Pecchi S, Burger M, et al. Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in phase I/II clinical trials. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; April 17-21, 2010; Washington, DC. Abstract 4498.
72. G. Edelman, C. Bedell, G. Shapiro A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies J Clin Oncol 2010 28 abstract 3004. Available at: www.asco.org. Accessed: December 31, 2012
73. Shapiro G, Edelman G, Calvo E, et al. Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA. Abstract 4497.
74. F.I. Raynaud, S.A. Eccles, S. Patel Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Mol Cancer Ther 8 2009 1725 1738
75. A.J. Folkes, K. Ahmadi, W.K. Alderton The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer J Med Chem 51 2008 5522 5532
76. S.M. Maira, F. Stauffer, J. Brueggen Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol Cancer Ther 7 2008 1851 1863
77. Laird AD, Avjioglu E. XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; April 14-18, 2007; Los Angeles, CA. Abstract B250.
78. I. Brana, P. LoRusso, J. Baselga A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies J Clin Oncol 2010 28 abstract 3030. Available at: www.asco.org. Accessed: December 31, 2012.
79. R. Sedrani, S. Cottens, J. Kallen Chemical modification of rapamycin: the discovery of SDZ RAD Transplant Proc 30 1998 2192 2194
80. Metcalf CA, III, Bohacek R, Rozamus LW, et al. Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. Proceedings of the Annual Meeting of the American Association for Cancer Research; March 27-31, 2004; Orlando, FL. Abstract 573-b.
81. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779 Drugs R D 5 2004 363 367
82. H. Hirai, H. Sootome, Y. Nakatsuru MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo Mol Cancer Ther 9 2010 1956 1967
83. Brokx R, Fletcher G, Bray M. MKC-1 interacts with multiple protein targets: characterization by induced fluorescence. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; April 18-22, 2009; San Diego, CA. Abstract 5353
84. C. Moldovan, J. Soria, P. LoRusso A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor, XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors J Clin Oncol 28 2010 3070
85. R.B. Cohen, P.A. Janne, J.A. Engelman A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors J Clin Oncol 28 2010 abstract 3015
86. G.J. Riely, M.G. Kris, B. Zhao Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus Clin Cancer Res 13 2007 5150 5155
87. D.T. Milton, G.J. Riely, C.G. Azzoli Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer Cancer 110 2007 599 605
88. S.S. Ramalingam, R.D. Harvey, N. Saba Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer Cancer 116 2010 3903 3909
89. F.R. Khuri, T.K. Owonikoko, J. Subramanian Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study J Clin Oncol 2011 29 abstract e13601. Available at: www.asco.org. Accessed: December 31, 2012
90. N.B. Leighl, J. Soria, J. Bennouna Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 2010 28 abstract 7524. Available at: www.asco.org. Accessed: December 31, 2012
91. G.M. Blumenthal, M.S. Ballas, W. Bernstein A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC J Clin Oncol 2010 28 abstract 7600. Available at: www.asco.org. Accessed: December 31, 2012
92. T. Kosaka, E. Yamaki, A. Mogi Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer J Biomed Biotechnol 2011 2011 165214